Abstract
A marked fall in urinary 5-HIAA excretion followed administration of chlorpromazine to a patient with known malignant carcinoid. Intestinal hypermotility, one manifestation of the so-called "carcinoid syndrome" was likewise suppressed during administration of the drug.